PDACNCT07573215
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
A study testing daraxonrasib in people with PDAC and PDAC - Pancreatic Ductal Adenocarcinoma, run by Revolution Medicines, Inc. at 257 sites in 2 countries.
Trial summary
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma
- What is being tested?
- daraxonrasib
- Type of treatment
- Pill or oral medicine
- How many people
- Not given
- Where
- 257 sitesin 2 countries
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Who may be able to join
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed PDAC with metastatic disease.
- Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
- At least one prior line of systemic therapy in the metastatic setting, which must include either a fluoropyrimidine-based or gemcitabine-based regimen.
- Received and progressed, been intolerant to prior standard therapy, or no longer expected to benefit from standard therapies.
Show all 9Show fewer
- Adequate bone marrow, renal, hepatic, and coagulation functions.
- Ineligible for, or unable to enroll in, another clinical trial of daraxonrasib, if available.
- Able to take oral medications
Who cannot join
- History of known central nervous system metastatic disease.
- Concurrent systemic anticancer therapy.
- Significant cardiovascular disease.
- Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).
- Active uncontrolled systemic infection.
- Major surgery within 28 days before enrollment.
- Additional inclusion and exclusion criteria may apply.
Trial locations and contacts
257 sites in 2 countries.
257 sites in 2 countries
United States256 sites
New York Oncology Hematology
Albany, New York, 12206
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103
McFarland Clinic
Ames, Iowa, 50010
Alaska Oncology and Hematology
Anchorage, Alaska, 99508
University of Michigan
Ann Arbor, Michigan, 48109
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54611
Illinois Cancer Specialist
Arlington Heights, Illinois, 60005
Piedmont Cancer Institute - Atlanta
Atlanta, Georgia, 30318
Piedmont Physicians Medical Oncology
Atlanta, Georgia, 30318
Emory University Hospital
Atlanta, Georgia, 30322
North Side Hospital - Atlanta Cancer Care
Atlanta, Georgia, 30342
Rocky Mountain Cancer Center
Aurora, Colorado, 80012
Johns Hopkins
Baltimore, Maryland, 21231
St. Luke's University Health Network
Bethlehem, Pennsylvania, 18015
University of Iowa Cancer Services Quad Cities
Bettendorf, Iowa, 52722
Alabama Oncology
Birmingham, Alabama, 35243
Lynn Cancer Institute - Boca Raton Regional Hospital
Boca Raton, Florida, 33487
St Luke's Cancer Institute
Boise, Idaho, 83712
Massachusetts General Hospital
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Hirschfeld Oncology
Brooklyn, New York, 11206
Dosik Hematology and Oncology
Brooklyn, New York, 11215
Advanced Cancer Treatment Centers
Brooksville, Florida, 36413
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Lahey Clinic
Burlington, Massachusetts, 01805
University of Vermont Medical Center
Burlington, Vermont, 05401
Allegheny Health Network Cancer Institute
Butler, Pennsylvania, 15212
MD Anderson at Cooper
Camden, New Jersey, 08103
Blood and Cancer Center
Canfield, Ohio, 44406
Aultman Hospital
Canton, Ohio, 44170
Cancer and Blood Specialists of Arizona
Casa Grande, Arizona, 85122
Mercy Medical Center
Cedar Rapids, Iowa, 52403
Bon Secours St. Francis Cancer Center
Charleston, South Carolina, 29414
Atrium Health
Charlotte, North Carolina, 28204
Northwestern University
Chicago, Illinois, 60611
University of Chicago Medical Center
Chicago, Illinois, 60637
Care Oncology Center
Chula Vista, California, 91911
OHC (Oncology Hematology Care)
Cincinnati, Ohio, 45242
UH Seidman Cancer Centre
Cleveland, Ohio, 44106
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
Cleveland Clinic Foundation
Cleveland, Ohio, 95000
UC Health Memorial Health System
Colorado Springs, Colorado, 80920
University Hospital - MU Health Care
Columbia, Missouri, 65212
Piedmont Columbus Regional Midtown
Columbus, Georgia, 31904
Jasonway Cancer Center
Columbus, Ohio, 43214
Ohio Health
Columbus, Ohio, 43214
OhioHealth Mansfield Hospital
Columbus, Ohio, 43214
Zangmeister Cancer Center
Columbus, Ohio, 43219
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43221
Samaritan Hemotology and Oncology
Corvallis, Oregon, 97330
University of Texas Southwestern Medical
Dallas, Texas, 75390
Southern Cancer Center
Daphne, Alabama, 36526
Premier Health OH
Dayton, Ohio, 45459
AdventHealth Porter
Denver, Colorado, 80210
Intermountain Health
Denver, Colorado, 80211
Karmanos Cancer Institute (Barbara Ann Karmanos Cancer Hospital)
Detroit, Michigan, 48201
Henry Ford Health
Detroit, Michigan, 48202
Dothan Hematology and Oncology
Dothan, Alabama, 36303
Advocate Health Care
Downers Grove, Illinois, 60515
City of Hope Cancer Center (California)
Duarte, California, 91010
Essentia Health
Duluth, Minnesota, 55805
Hematology & Oncology Associates of NEPA
Dunmore, Pennsylvania, 18512
CommonSpirit Oncology Mercy
Durango, Colorado, 81301
Duke Cancer Institute
Durham, North Carolina, 27710
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017
USOR: Minnesota Oncology Hematology, PA
Edina, Minnesota, 55435
DHR Health
Edinburg, Texas, 78539
Inova Schar Cancer
Fairfax, Virginia, 22031
Virginia Cancer Specialists
Fairfax, Virginia, 22031
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58102
McLeod Health
Florence, South Carolina, 29506
Summit Health
Florham Park, New Jersey, 07932
William Beaumont Army Medical Center - Fort Bliss
Fort Bliss, Texas, 79918
UCHealth Poudre Valley Hospital
Fort Collins, Colorado, 80528
Alabama Cancer Care of Ft Payne
Fort Payne, Alabama, 35967
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Parkview Packnett Family Cancer Institute
Fort Wayne, Indiana, 46845
Cancer and Blood Specialty Clinics
Fountain Valley, California, 92708
Frederick Health
Frederick, Maryland, 21701
Hematology Oncology Associates of Fredericksburg
Fredericksburg, Virginia, 22408
California Cancer Associates for Research and Excellence
Fresno, California, 93720
Providence St. Jude
Fullerton, California, 92835
West Cancer Center
Germantown, Tennessee, 38138
City of Hope Phoenix
Goodyear, Arizona, 85338
Aurora Medical Center
Grafton, Wisconsin, 53024
The Cancer & Hematology Centers
Grand Rapids, Michigan, 49546
HSHS St. Mary's Hospital Medical Center
Green Bay, Wisconsin, 54303
Bellin Health
Green Bay, Wisconsin, 54313
Marin Cancer Care
Greenbrae, California, 94904
Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute
Greer, South Carolina, 29651
Virginia Oncology Associates
Hampton, Virginia, 23606
Compass Oncology
Happy Valley, Oregon, 97223
Memorial Cancer Institute
Hollywood, Florida, 33021
The Queen's Medical Center
Honolulu, Hawaii, 96813
Hawai'i Pacific Health
Honolulu, Hawaii, 96814
Genesis Cancer and Blood Institute
Hot Springs, Arkansas, 71913
American Oncology Network - Oncology Consultants
Houston, Texas, 77024
Houston Methodist Hospital- Cancer Center
Houston, Texas, 77030
MD Anderson Cancer Center
Houston, Texas, 77030
Carolina BioOncology Institute
Huntersville, North Carolina, 28078
Indiana University School of Medicine
Indianapolis, Indiana, 46202
Franciscan Alliance Health
Indianapolis, Indiana, 46237
Jackson Oncology Associates
Jackson, Mississippi, 39202
Mayo Clinic - Florida
Jacksonville, Florida, 32224
Cancer Specialists of North Florida
Jacksonville, Florida, 32256
Mercy Hospital Joplin
Joplin, Missouri, 64804
Logan Health
Kalispell, Montana, 59901
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Mid America Cancer Care
Kansas City, Missouri, 64132
Kadlec Regional Medical Center
Kennewick, Washington, 99336
Kettering Health Cancer Center
Kettering, Ohio, 45429
Tennessee Cancer Specialists
Knoxville, Tennessee, 37919
Emplify Health by Gundersen
La Crosse, Wisconsin, 05461
Northwell Health
Lake Success, New York, 11042
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Baptist Health Lexington
Lexington, Kentucky, 40503
NHO Revive Research Institute
Lincoln, Nebraska, 68506
Carti Cancer Center
Little Rock, Arkansas, 72205
Memorial Sloan Kettering Cancer Center
Long Island City, New York, 11101
USC Norris Comprehensive Cancer Hospital
Los Angeles, California, 90033
Cedars-Sinai Medical Center
Los Angeles, California, 90048
UCLA Health Westlake Village
Los Angeles, California, 90095
University of California
Los Angeles, California, 90095
Norton Cancer Institute
Louisville, Kentucky, 40217
Covenant Health - Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410
Central Georgia Cancer Care
Macon, Georgia, 31210
University of Wisconsin
Madison, Wisconsin, 53792
Northwest Georgia Oncology Centers
Marietta, Georgia, 30060
Lindenberg Cancer & Hematology Center
Marlton, New Jersey, 08053
Marshfield Medical Center
Marshfield, Wisconsin, 54449
Alliance Cancer Specialists
Media, Pennsylvania, 19063
Baptist Cancer Center
Memphis, Tennessee, 38120
Advent Health Shawnee Mission
Merriam, Kansas, 66204
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136
Baptist Hospital of Miami
Miami, Florida, 33176
Mount Sinai Medical Center of Florida
Miami Beach, Florida, 33140
Premier Health OH
Middletown, Ohio, 45005
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
USA Health Mitchell Cancer Institute
Mobile, Alabama, 36604
Southern Cancer Center
Mobile, Alabama, 36608
Pacific Cancer Care
Monterey, California, 93940
Montgomery Cancer Center
Montgomery, Alabama, 36106
Overlook Medical Center - Medical Diagnostic Associates - Atlantic Medical Group
Morristown, New Jersey, 07960
El Camino Health
Mountain View, California, 94040
Endeavor Health Cancer Institute
Naperville, Illinois, 60126
Florida Cancer Specialists and Research Institute
Naples, Florida, 32746
Sarah Cannon Cancer Institute
Nashville, Tennessee, 37203
Tennessee Oncology
Nashville, Tennessee, 37203
Mountain Health Clinic
Natick, Massachusetts, 01760
Allegheny Valley Hospital
Natrona Heights, Pennsylvania, 15212
Rutgers Cancer Institute
New Brunswick, New Jersey, 08903
Yale New Haven Hospital
New Haven, Connecticut, 06519
LSU LCMC Health Cancer Center
New Orleans, Louisiana, 70112
Ochsner Health System
New Orleans, Louisiana, 70121
NYU Langone Health
New York, New York, 10016
Columbia University
New York, New York, 10022
The Mount Sinai Hospital
New York, New York, 10029
Columbia University Irving Medical Center
New York, New York, 10032
New York Cancer and Blood Specialists
New York, New York, 11967
Ascension Medical Group St. Vincent
Newburgh, Indiana, 47630
Deaconess Health System
Newburgh, Indiana, 47630
Riverside Health
Newport News, Virginia, 23320
Norwalk Hospital
Norwalk, Connecticut, 06856
Eastern Connecticut Hematology and Oncology
Norwich, Connecticut, 06360
University of California - San Francisco
Oakland, California, 94158
Ogden Clinic
Ogden, Utah, 84405
OU Health Science Center - Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
University of Nebraska Medical Center
Omaha, Nebraska, 68114
Nebraska Cancer Specialists
Omaha, Nebraska, 68130
UCI Health
Orange, California, 92612
Advent Health
Orlando, Florida, 32803
Holy Cross Health - Phil Smith Neuroscience Institute ALS Multidisciplinary Clinic
Orlando, Florida, 33308
Owensboro Health Mitchell Memorial Cancer Center
Owensboro, Kentucky, 42303
Mercy Health - Paducah Cancer Center
Paducah, Kentucky, 42003
Desert Care Network Comprehensive Cancer
Palm Springs, California, 92262
Paoli Hospital
Paoli, Pennsylvania, 19301
Texas Oncology
Pearland, Texas, 77584
Ascension Sacred Heart
Pensacola, Florida, 32504
Illinois CancerCare
Peoria, Illinois, 61615
OSF Cancer Institute
Peoria, Illinois, 61637
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Mayo Clinic - Arizona
Phoenix, Arizona, 85054
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania, 15224
UPMC Western Maryland
Pittsburgh, Pennsylvania, 15224
Providence Medical Center
Portland, Oregon, 97213
Beacon Clinic
Post Falls, Idaho, 83854
Rhode Island Hospital
Providence, Rhode Island, 02903
Blessing Hospital
Quincy, Illinois, 62301
Monument Health Cancer Care Institute
Rapid City, South Dakota, 57701
Seattle Integrative Cancer Center
Renton, Washington, 98057
Methodist Richardson Cancer Center
Richardson, Texas, 75082
VCU Health
Richmond, Virginia, 23219
Virginia Cancer Institute
Richmond, Virginia, 23229
Mayo Clinic Minnesota
Rochester, Minnesota, 55905
Rochester Regional Health
Rochester, New York, 14626
Northwest Oncology & Hematology
Rolling Meadows, Illinois, 60008
The Kaiser Permanente Medical Group
Roseville, California, 95661
Hematology Oncology Consultants
Royal Oak, Michigan, 48073
Sutter Health
Sacramento, California, 95816
Covenant HealthCare
Saginaw, Michigan, 48604
Health Partners Frauenshuh Cancer Center
Saint Louis Park, Minnesota, 55426
HealthPartners Frauenshuh Cancer Center
Saint Louis Park, Minnesota, 55426
Park Nicollet Specialty Center
Saint Louis Park, Minnesota, 55426
Health Partners Oncology
Saint Paul, Minnesota, 55101
Oregon Oncology Specialists
Salem, Oregon, 97301
Utah Cancer Specialists (UCS)
Salt Lake City, Utah, 84106
Huntsman Cancer Institute & Hospital
Salt Lake City, Utah, 84112
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas, 78229
Scripps Clinic Torrey Pines
San Diego, California, 92037
Sutter Health
San Francisco, California, 94115
Bakar Precision Cancer Medicine Building
San Francisco, California, 94143
CommonSpirit
San Luis Obispo, California, 93401
Providence Medical Foundation
Santa Rosa, California, 95403
Intercoastal Medical Group
Sarasota, Florida, 34232
Guthrie Sayre
Sayre, Pennsylvania, 18840
Honor Health
Scottsdale, Arizona, 85258
Virginia Mason Medical Center
Seattle, Washington, 98101
Providence Swedish Cancer Institute
Seattle, Washington, 98104
Swedish Cancer Institute Treatment Center
Seattle, Washington, 98104
Fred Hutch Cancer Center
Seattle, Washington, 98109
Willis Knighton Cancer Center
Shreveport, Louisiana, 71103
Sanford Health
Sioux Falls, South Dakota, 57104
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Mercy Hospital Springfield
Springfield, Missouri, 65807
Oncology Hematology Associates
Springfield, Missouri, 65807
Willamette Valley Cancer Institute
Springfield, Oregon, 97477
Mercy Hospital St. Louis-South
St Louis, Missouri, 63128
Pratt Cancer Center
St Louis, Missouri, 63141
Washington University School of Medicine
St Louis, Missouri, 63141
Stanford University
Stanford, California, 94305
Stony Brook University Hospital
Stony Brook, New York, 11794
Tampa General Hospital
Tampa, Florida, 33606
Moffitt Cancer Center
Tampa, Florida, 33612
Baylor Scott & White Health
Temple, Texas, 76508
Montefiore Medical Center
The Bronx, New York, 10461
Community Medical Center
Toms River, New Jersey, 08755
New England Cancer Specialists
Topsham, Maine, 04086
University of Arizona Cancer Center
Tucson, Arizona, 85719
Alabama Cancer Care of Tuscaloosa
Tuscaloosa, Alabama, 35406
NorthBay Health Heidi Y Campini Cancer Center
Vacaville, California, 95687
Providence St. Mary Medical Center
Walla Walla, Washington, 99362
UCSF John Muir Health
Walnut Creek, California, 94598
University of Iowa
Waukee, Iowa, 50263
UW Health Cancer Center at ProHealth Care
Waukesha, Wisconsin, 53072
UPMC Hillman Cancer Center
West Mifflin, Pennsylvania, 15122
University of Kansas Medical Center
Westwood, Kansas, 66205
Cancer Center of Kansas
Wichita, Kansas, 67214
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
UMass Memorial Medical Center
Worcester, Massachusetts, 01655
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
Trinity Health Hospital
Ypsilanti, Michigan, 48197
City of Hope Chicago
Zion, Illinois, 60099
About this study
Official title: Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
Read the detailed description
This EAP has been established to provide access to daraxonrasib to patients with previously treated metastatic pancreatic adenocarcinoma during the period before potential commercial availability. Patients may be eligible if they have progressed on, are intolerant of, or are no longer expected to benefit from available standard therapies, and if they are not able to enroll in a clinical trial of daraxonrasib due to ineligibility or lack of access. This EAP is intended to address an unmet medical need and is not designed to support clinical development objectives.
Daraxonrasib is an investigational, orally administered, RAS(ON) inhibitor administered as monotherapy. Daraxonrasib will be supplied by the Sponsor free of charge during the duration of treatment under this program.
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
- Being tested
- daraxonrasib
- Keywords
- Expanded Access Program (EAP), EAP, Daraxonrasib, RMC-6236, RMC-0706236, Metastatic pancreatic adenocarcinoma, Pancreatic ductal adenocarcinoma (PDAC), RAS(ON) inhibitor, Unmet medical need, Pancreatic cancer, RAS, KRAS, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma, Pancreatic Adenocarcinoma, Compassionate Use
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
daraxonrasibDrug
Also called RMC-6236, RMC-0706236
Oral tablets administered once daily
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PDACStudies of the same condition, open and under way.
- More trials run by Revolution Medicines, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Revolution Medicines, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07573215
- Sponsor's protocol ID
- RMC-6236-401
- Status last verified
- Jul 2026
- First submitted
- 1 May 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
- ClinicalTrials.gov ID
- NCT07573215
- Acronym / sponsor ID
- RMC-6236-401
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
- Keywords
- Expanded Access Program (EAP), EAP, Daraxonrasib, RMC-6236, RMC-0706236, Metastatic pancreatic adenocarcinoma, Pancreatic ductal adenocarcinoma (PDAC), RAS(ON) inhibitor
- Study type
- Expanded access
- Recruitment status
- Approved For Marketing
- Lead sponsor
- Revolution Medicines, Inc.Industry (pharma, biotech, devices)
- First posted
- 7 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
Detailed description
This EAP has been established to provide access to daraxonrasib to patients with previously treated metastatic pancreatic adenocarcinoma during the period before potential commercial availability. Patients may be eligible if they have progressed on, are intolerant of, or are no longer expected to benefit from available standard therapies, and if they are not able to enroll in a clinical trial of daraxonrasib due to ineligibility or lack of access. This EAP is intended to address an unmet medical need and is not designed to support clinical development objectives.
Daraxonrasib is an investigational, orally administered, RAS(ON) inhibitor administered as monotherapy. Daraxonrasib will be supplied by the Sponsor free of charge during the duration of treatment under this program.
Study design
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed PDAC with metastatic disease.
- Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
- At least one prior line of systemic therapy in the metastatic setting, which must include either a fluoropyrimidine-based or gemcitabine-based regimen.
Key exclusion criteria (7 listed)
- History of known central nervous system metastatic disease.
- Concurrent systemic anticancer therapy.
- Significant cardiovascular disease.
- Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).
- Active uncontrolled systemic infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| daraxonrasibAlso: RMC-6236, RMC-0706236Oral tablets administered once daily | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Related InfoLink provided by the sponsor.
Related trials for PDAC
RecruitingPhase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
RecruitingPhase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
RecruitingPhase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Cancer, PDAC
RecruitingPhase 1/2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
257 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing daraxonrasib in people with PDAC and PDAC - Pancreatic Ductal Adenocarcinoma, run by Revolution Medicines, Inc. at 257 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 257 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.